Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Active Sjogren's Syndrome (NEPTUNUS-2)
NCT05349214Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- May 2025
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjogren's syndrome (3 arms), sponsored by Novartis. Primary endpoint: EULAR Sjogren's Syndrome Disease Activity Index at 48 weeks. Started Aug 2022; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT05349214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349214.